Amgen-Horizon Deal May Signal FTC’s Return To Bargaining
September 13, 2023
By: Laura C. Onken
On Sept. 1, just over a week before trial was slated to begin, the Federal Trade Commission and several states agreed to settle their challenge to Amgen Inc.'s proposed acquisition of Horizon Therapeutics, allowing the transaction to close.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
ACI Forum on Pharma & Biotech Patent Litigation USA 2025
Speaking Engagement
Intellectual Property
CCWC 21st Annual Career Strategies Conference
Speaking Engagement
Fordham 52nd Annual Conference on International Antitrust Law and Policy
Speaking Engagement
Antitrust
Kisaco Research Trade Secret Legal Protection Conference 2025
Speaking Engagement
Intellectual Property
SCCE 23rd Annual Compliance & Ethics Institute
Speaking Engagement
Antitrust
29th Annual IBA Competition Conference
Sponsorship
Antitrust
Key Appellate Decisions Shaping Antitrust Strategy
Webinar
Antitrust
New Frontiers of Antitrust – 16th Annual International Conference of Concurrences Review
Speaking Engagement
Antitrust
MCCA Pathways Conference
Sponsorship
Antitrust
HNBA/VIA Annual Convention 2025
Sponsorship
Antitrust